Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy

Diabetes, Obesity and Metabolism

Volumn 17, Issue 2, 2015, Pages 202-206

  Hollander, Priscilla ^a   King, A B ^b   Del Prato, S ^c   Sreenan, S ^d   Balci, M K ^e   Munoz Torres M ^f   Rosenstock, J ^g   Hansen, C T ^h   Niemeyer, M ⁱ   Garber, A J ^j  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Diabetes Care Center   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d Royal College of Surgeons in Ireland   (Ireland)

^e AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^h NOVO NORDISK A S   (Denmark)

ⁱ Novo Nordisk Pharma GmbH   (Germany)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Glycaemic control; Hypoglycaemia; Insulin degludec; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN;

ACUTE CORONARY SYNDROME; BLEEDING; BODY WEIGHT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DEATH; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN TREATMENT; LETTER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; TREATMENT OUTCOME;

EID: 84921326512     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12411     Document Type: Letter

References (6)

1. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
2. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
3. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
4. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
5. Meneghini LF, Harris SB, Evans M, Rasmussen S, Johansen T, Pieber TR. Lower within-subject variability in mean blood glucose concentration with insulin degludec vs. insulin glargine: a meta-analysis of patients with T2D. Diabetes 2013; 62(Suppl. 1): A232, abstract 914-P.
6. Heller SR, Mathieu C, Kapur R, Wolden ML, Zinman B. Rate ratios for nocturnal confirmed hypoglycemia with insulin degludec vs. insulin glargine using different definitions. Diabetes 2014; 63(Suppl. 1): A106, abstract 402-P.